Last reviewed · How we verify
Imiglucerase GZ437843
Imiglucerase is a recombinant glucocerebrosidase enzyme that breaks down glucocerebroside, a lipid that accumulates in Gaucher disease.
Imiglucerase is a recombinant glucocerebrosidase enzyme that breaks down glucocerebroside, a lipid that accumulates in Gaucher disease. Used for Gaucher disease type 1, Gaucher disease type 3.
At a glance
| Generic name | Imiglucerase GZ437843 |
|---|---|
| Also known as | Cerezyme |
| Sponsor | Sanofi |
| Drug class | Enzyme replacement therapy |
| Target | Glucocerebrosidase (β-glucosidase) |
| Modality | Small molecule |
| Therapeutic area | Rare genetic disease / Lysosomal storage disorder |
| Phase | Phase 3 |
Mechanism of action
Imiglucerase is an enzyme replacement therapy that provides functional glucocerebrosidase to patients with Gaucher disease, a lysosomal storage disorder caused by deficiency of this enzyme. By catalyzing the hydrolysis of glucocerebroside to glucose and ceramide, it reduces pathological lipid accumulation in macrophages and other tissues, thereby alleviating disease manifestations.
Approved indications
- Gaucher disease type 1
- Gaucher disease type 3
Common side effects
- Infusion-related reactions
- Headache
- Fatigue
- Arthralgia
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiglucerase GZ437843 CI brief — competitive landscape report
- Imiglucerase GZ437843 updates RSS · CI watch RSS
- Sanofi portfolio CI